• Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Before Header

 TudorRose Consulting is now part of Adjutor Healthcare.   Same team.   More Expert Services.    Meet Adjutor

This is the official © Adjutor Healthcare Logo. It is subject to copyright and may not be used in any way or form without the express permission of Adjutor Healthcare Pty Ltd.

A global provider of development and commercialisation services to the pharmaceutical, biotechnology and medical device industries.

  • What We Do
  • Why Choose Us
  • Who We Are
  • Helpers Blog
  • Join Our Team
  • Contact Us
  • What We Do
  • Why Choose Us
  • Who We Are
  • Helpers Blog
  • Join Our Team
  • Contact Us

Australian Government Cash Splash on High Tech Recovery

October 15, 2020 //  by Adjutor Healthcare

Australian science and technology sectors are talking about a ‘research revival’ as the Federal Government splashes the cash in the 2020 Budget.

2020 Budget Cash Splash

Image depicts the Australian government 2020 budget cash splash on high tech and science recovery.

Thanks to COVID-19, early October saw the first Australian federal budget delivered in a recession in 30 years.

The Treasurer said personal income tax cuts, infrastructure spending, and business incentives would create jobs and boost consumer spending.

The government is clearly signalling a shift to high technology by announcing the following priorities areas for investment:

  • Resources technology and critical minerals
  • Food and beverages
  • Medical products
  • Recycling and clean energy
  • Defence
  • Space

Support for the refundable component of the Research and Development Tax Incentive has been increased 5 percentage points from earlier proposals and the much feared $4 million cap that had been proposed on annual cash refunds won’t be implemented.

The R&D expenditure threshold has also increased from $100 million to $150 million (previously announced).

The budget retains the current level of support for Small and Medium-sized Enterprises (SME’s) providing certainty and investment confidence.

2020 Budget Secures Industry Wide Support

The budget has been welcomed by the Biotech, Pharma and Medtech industries, who had all submitted their policy priorities to the Government.

AusBiotech

AusBiotech has stated that they believe the Research and Development Tax Incentive (RDTI), alongside support for medical manufacturing, will incentivise R&D and manufacturing growth.

Medicines Australia

Medicines Australia has welcomed the guaranteed funding commitment, worth at least $2.8 billion over 4 years, which will bring greater certainty for Australian patient access to new and innovative medicines.

An important point to note is that this guarantee removes the requirement for a cost offset for new medicine listings on the Pharmaceutical Benefits Scheme (PBS). This will allow medicines to be listed for reimbursement faster, without the need to find additional savings from other parts of the health budget.

The Government has also committed to maintaining the transformation of health delivery seen with COVID-19, including home delivery of medicines, tele-health and digital reforms to the TGA.

An allocation of $12 million has been recommended for upgrading the TGA’s IT systems, which were developed in the late 1990s, and will ensure the TGA is in a position to track applications and be better placed to approve life-changing and lifesaving medical technology innovations.

Medical Technology Association of Australia (MTAA)

The Medical Technology Association of Australia (MTAA) has also praised the budget.

The budget includes $3.3 billion for the COVID National Medical Stockpile, which includes $9.2 million for increasing onshore mask manufacturing capability. MTAA made a recommendation that the government replenish and build the stockpile with a portion of locally manufactured essential items, which will ensure the industry cements its place in the ongoing provision of healthcare to Australians.

Medicines Australia CEO, Ms Elizabeth de Somer, summed up the budget well –

“This historic budget will bring substantial changes to the healthcare system, and Medicines Australia looks forward to working with the Government on implementing these essential reforms and contributing to Australia’s health led economic recovery”.


Our Global Specialists Can Help You

Adjutor Healthcare is ideally positioned to assist local and international companies make the most of the changes announced, whether you want to develop, manufacture, or have a product approved in Australia.

Contact us for a confidential discussion on how we can help you to move ahead.


Share this post:

TwitterFacebookLinkedInEmail

Category: Adjutor HealthcareTag: Biotech, Clinical Trials, Commercialization, Development, Federal Budget, Manufacturing, Medical Devices, Medicines, Medtech, PBS, Pharma, Therapeutic Goods

No time to waste?

Contact us today for an initial consultation and learn
how we can add value to your business.

CONTACT US TODAY

You May Also Be Interested In…

Despite the postponement of the EU Medical Devices Regulation implementation to May 2021 appearing to offer breathing room, it has actually shortened the transition time for many manufacturers!

EU MDR: Are ROW Device Sponsors Ready for the Ripple Effect?

Image depicts the Australian government 2020 budget cash splash on high tech and science recovery.

Australian Government Cash Splash on High Tech Recovery

TGA's new Product Information (PI) Form: If you need support to meet the 31 December 2020 deadline, we’re here to help.

The Pointy End of the PI Reformatting Transition Period

Therapeutic Product Commercialization - We may have a global market but do we really consider options outside of USA and EU enough when developing our strategy?

Therapeutic Product Commercialization

Medsafe NZ has been working on a new therapeutic products regulatory regime to replace and modernise the regulatory arrangements for medicines.

MEDSAFE NZ Moves Ahead in 2020

Adjutor Healthcare announces launch of Adjutor Healthcare New Zealand Limited consulting and sponsorship entity for medicines and medical devices.

Launch of Adjutor Healthcare (NZ) Limited

The Federal Court imposes $10 million penalty for the alleged Peptide Clinics advertising breaches. Peptide Clinics Pty Ltd was liquidated earlier this year.

Consumer Insecurity / Vanity Targeted by TGA – Massive Fines

Australian Employment Regulations - Compliance Alert Banner.

Australian Employment Regulations

The TGA has released new guidelines for Advertizing Therapeutic Goods in 2019. Image depicts Fireworks over Sydney Harbour Bridge, New Years Eve January 2019

Advertizing Therapeutic Goods in Australia

Footer

Company Profile

Adjutor Healthcare Pty Ltd is part of a worldwide network that spans 90 countries.

We provide seamless services across development and commercialization of your products internationally.

Read More

Contact Us

Adjutor Healthcare Pty Ltd

  +61 418 314 763

  rosalie.cull@adjutor.com.au

  • Email
  • LinkedIn
  • Phone

Email Newsletter

Sign up to receive the latest industry news updates!

© 2021 Adjutor Healthcare · All Rights Reserved · Web Services by Kracked Kreative
We use cookies to ensure that you have the best experience on our website.OKPrivacy policy